Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers N > Headlines for New River Pharmaceuticals Inc. > News item |
Merrill puts New River at buy
New River Pharmaceuticals Inc: is rated at a buy by Merrill Lynch analyst David Munno. The analyst believes the company provides investors with a strong risk/reward going into the Food and Drug Administration decision for the approval and scheduling for NRP104. Expect an estimated $10 to $15 or more of upside and $5 to $10 of downside on the approval decision, says Merrill. The best case would be if FDA gives NRP104 an approvable letter requiring no new studies or full approval. Shares of the Radford, Va.-based pharmaceutical company were up 9 cents, or 0.39%, at $23.90. (Nasdaq: NRPH)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.